IMUNON Announces Announces Topline Results From Phase 2 OVATION 2 Study With IMNN-001; Results showed 11.1 Month In Median Overall Survival vs Standard-Of-Care Alone In Intent-To-Treat Population
Portfolio Pulse from Benzinga Newsdesk
IMUNON announced topline results from its Phase 2 OVATION 2 study with IMNN-001, showing a median overall survival of 11.1 months compared to standard-of-care alone in the intent-to-treat population.
July 30, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IMUNON's Phase 2 OVATION 2 study with IMNN-001 demonstrated a median overall survival of 11.1 months, which is an improvement over the standard-of-care alone. This positive result could boost investor confidence and potentially drive the stock price up in the short term.
The positive topline results from the Phase 2 study indicate that IMNN-001 has a significant impact on patient survival, which is likely to be viewed favorably by investors. This could lead to a short-term increase in the stock price as the market reacts to the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100